CHAPEL HILL, N.C., Aug. 6 /PRNewswire/ -- Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs. The structure, activities, and resources of New Product Planning (NPP) groups are critical to focusing new product development and optimizing product portfolios.
A new benchmarking study from Best Practices, LLC found that while creating a potential therapy's Target Product Profile is a central focus of early NPP activities, only 50 percent of Global NPP groups in large companies begin creating the target profile in the pre-clinical development phase.
To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr969.htm .
The study, Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability, identifies the full set of activities that NPP groups perform across the development cycle as well as the structure and roles of NPP groups. The research examines dozens of NPP developmental activities in terms of timing during the development process, intended outcomes and value for the organization. In addition, the study details the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolve as a company matures.
Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies. The research report reflects the current state of New Product Planning efforts at best-in-class organizations such as Abbott, Astellas, Bayer, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Sanofi-Aventis, Wyeth and others.
Topics covered in this study include:
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved